Phage Therapy For Chronic Lyme Disease? Part One

Phage Therapy For Chronic Lyme Disease? Part One

What is Phage Therapy? Although Eli Lilly (one of the largest pharmaceutical companies in the US) promoted phage therapy commercially until antibiotics became popular and now it is virtually unknown in the United States. However, phage therapy has been practiced successfully in Russia and other parts of the world for ninety years.

The following information was provided by Professor Zemphira Alavidze, PhD, Head of Laboratory Phage Morphology and Biology at the Eliava Institute of Bacteriophages, Morphology, and Virology which is a part of the Georgian Academy of Sciences in the Republic of Georgia.

To begin with, bacteriophages or “œphagea” are viruses that invade bacterial cells and, in the case of lytic phages, disrupt bacterial metabolism and cause the bacterium to destruct. Phage Therapy is the therapeutic use of lytic bacteriophages to treat pathogenic bacterial infections.

The bacterial host range of phage is generally narrower than that found in the antibiotics that have been selected for clinical applications.

Most phage are specific for one species of bacteria and many are only able to destroy specific strains within a species. This limited host range can be advantageous, in principle, as phage therapy results in less harm to the normal body flora and ecology than commonly used antibiotics, which often disrupt the normal gastrointestinal flora and result in opportunistic secondary infections by organisms such as Clostridium difficile.

The potential clinical disadvantages associated with the narrow host range of most phage strains is addressed through the development of a large collection of well-characterized phage for a broad range of pathogens, and methods to rapidly determine which of the phage strains in the collection will be effective for any given infection.

Phage therapy can be very effective in certain conditions and has some unique advantages over antibiotics.

Bacteria also develop resistance to phages as they do antibiotics, but it is incomparably easier to develop new phage than new antibiotic. A few weeks versus years are needed to obtain new phage for new strain of resistant bacteria. As bacteria evolve resistance, the relevant phages naturally evolve alongside.

When super bacterium appears, the super phage already attacks it. We just need to derive it from the same environment. Phages have special advantage for localized use, because they penetrate deeper as long as the infection is present, rather than decrease rapidly in concentration below the surface like antibiotics. The phages stop reproducing once as the specific bacteria they target are destroyed.

Phages do not develop secondary resistance, which is quite often in antibiotics. With the increasing incidence of antibiotic resistant bacteria and a deficit in the development of new classes of antibiotics to counteract them, there is a need to apply phages in a range of infections.

Lytic phages are similar to antibiotics in that they have remarkable antibacterial activity. However, therapeutic phages have some advantages over antibiotics, and phages have been reported to be more effective than antibiotics in treating certain infections in humans and experimentally infected animals.

For example, in one study, Staphylococcus aureus phages were used to treat patients having purulent disease of the lungs and pleura. The patients were divided into two groups; the patients in group A (223 individuals) received phages, and the patients in group B (117 individuals) received antibiotics.

Also, this clinical trial is one of the few studies using i.v. phage administration (48 patients in group A received phages by i.v. injection). The results were evaluated based on the following criteria: general condition of the patients, X-ray examination, reduction of purulence, and microbiological analysis of blood and sputum. No side effects were observed in any of the patients, including those who received phages intravenously.

Overall, complete recovery was observed in 82% of the patients in the phage-treated group as opposed to 64% of the patients in the antibiotic-treated group. Interestingly, the percent recovery in the group receiving phages intravenously was even higher (95%) than the 82% recovery rate observed with all 223 phage-treated patients.

This entry was posted in Alternative Treatment Protocols, Ask the Doctor, Chronic Lyme Disease, Coping with Lyme disease, Diagnosis of Lyme Disease, Lyme Disease Articles, Lyme Disease Treatment, Research and Development and tagged , , , . Bookmark the permalink.

One Response to Phage Therapy For Chronic Lyme Disease? Part One

  1. John says:

    Thanks Jenna,

    Here is where I first heard of phage therapy in a comprehensive Popular Science article (of all places):

    http://www.popsci.com/scitech/article/2009-03/next-phage

    This is the future of anti-biotic medicine.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>